Companies › Neurodawn Pharmaceutical
1 active drug program in 1 registered trial: 1 Phase 2; Other; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Y-4 combination of pregabalin (GABA analog) and riluzole (glutamate release inhibitor) | GABRA1, SLCX1 | Phase 2 | Postherpetic Neuralgia | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07275762 | Y-4 | Phase 2 | Postherpetic Neuralgia | Other | Nov 2026 |
Ono Pharmaceutical Seaport Therapeutics Lipocine UCB Biopharma SRL Haisco Pharmaceutical Group SK Life Science Sedana Medical Acacia Pharma Umecrine Cognition
Healx Skingenix Sensory Cloud Shanghai Huilun Pharmaceutical Dendrogenix
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.